Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 and CD22 Prime CAR-T for R/R B-ALL
NCT04781634Phase 2Recruiting
- Sponsor
- Chongqing Precision Biotech
- Start
- Mar 2021
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD19 and CD22 targeted prime CAR-T cells in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Chongqing Precision Biotech. Started Mar 2021; status: recruiting.
02
Drugs
CD19 and CD22 targeted prime CAR-T cells
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT04781634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04781634.